Biodesix operates in lung cancer diagnostic testing and biopharma services, specializing in personalized patient care and disease detection, evaluation, and treatment. The company provides diagnostic tests and biopharma services, self-described as transforming personalized diagnostics.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Biodesix, Inc. Common Stock

Biodesix specializes in lung cancer diagnostic testing and biopharma services, providing clinical diagnostic tests that aid in disease detection and treatment. Biodesix offers end-to-end diagnostic services, custom diagnostics development, and clinical sample testing.

COM:BIODESIX

Biodesix

Last Close

1.20

22/11 21:00

Market Cap

186.20M

Beta: -

Volume Today

702.98K

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics